Navigation Links
Generic Onslaught Makes Drug Pricing Decisions More Critical Than Ever
Date:1/3/2008

NEW YORK, Jan. 3 /PRNewswire/ -- In an era of expanding competition from generics, expiring patent protection for many top-selling drugs, and a slowdown in new drug discoveries, there is very little margin for error in drug pricing decisions. A new report by Kalorama Information entitled Drug Pricing and Reimbursement Strategies: Preparing for the Coming Generic Onslaught gives pharmaceutical companies the information they need to reevaluate their pricing strategies to remain profitable in a changing marketplace.

Pharmaceutical sales reached $643.0 billion worldwide in 2006, increasing by 6.5% over the previous year, and global pharmaceutical companies have enjoyed a median profitability more than three times the average for all Fortune 500 companies. But companies will be challenged in the coming years: in addition to the onslaught of generics, which have increased their market penetration from 44% to 51.6% in the last couple of years, shrinking government and corporate healthcare budgets are putting pressure on the pricing strategies of pharmaceutical and biotech companies and reducing their margins. After eight years of double-digit growth, commercial prescription drug costs decreased to the single digits in 2003 and settled at a 4.8% growth rate in 2005.

"The golden years of monopolistic pricing in the United States are gone," notes the report's author, Joseph Constance. "Medicare Part D initiation, tiered managed care formulary systems, and the increasing clout of generic medicines are challenging margins now. Companies will have to adapt to survive, and pricing is one of the few levers they can pull."

Kalorama Information's report, Drug Pricing and Reimbursement Strategies: Preparing for the Coming Generic Onslaught provides considerable detail on this all-important area of pharmaceutical marketing strategy in the United States, Europe and Japan. It not only exposes the current business environment for pharmaceuticals, but also details strategies for specific results, including: gaining and defending market share through the cautious application of penetration pricing, enhancing brand loyalty with the 'bait and hook' tactic, as well as strategies for gaining new customers, improving margins and utilizing capacity. The report can be purchased directly from Kalorama Information by visiting http://www.kaloramainformation.com/Guide-Drug-Pricing-1422997, and is also available at http://www.MarketResearch.com.

About Kalorama Information

Kalorama Information supplies the latest in independent market research on medical markets. For more information, contact Tom Ehart at 240-747-3014 or tehart@marketresearch.com, or visit http://www.KaloramaInformation.com.


'/>"/>
SOURCE Kalorama Information
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
2. Generic Prescription Drugs Show Increasingly Greater Use in Southeastern Pennsylvania
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
4. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
5. New OIG Report Confirms Part D Plans Are Driving Generic Utilization
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
7. Watson Files FDA Application for Generic YAZ(R)
8. Giant Eagle Expands Popular Generic Prescription Program and Now Offers 400 for $4
9. Barr Receives Tentative Approval for a Generic Version of Mirapex(R) Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg
10. Barrs Generic Version of Estrostep(R) Fe Tablets Approved
11. Amneal Pharmaceuticals & Indoco Remedies Finalize Long Term Joint Venture Agreement to Develop and Market Generic Ophthalmic Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with ... Latin America . ... ... ... ...
Breaking Medicine Technology: